Stroke and Announces U.

The trial is being conducted under an Investigational Device Exemption and the device is limited to investigational use in the United States.. Stroke and Announces U.S. Trial Of Unique Therapy for the closure of left atrial appendage, Medtronic announced today the successful implant of its Cardioblate Closure left atrial appendage occlusion by Dr. Patrick McCarthy, co-director of the Bluhm Cardiovascular Institute at Northwestern Memorial Hospital in Chicago, Illinois, as part of a U.S.

Published literature shows that the left atrial appendage is the main source of blood clots in the left atrium. Patients with an arrhythmia known as atrial fibrillation have an increased risk of clot formation. As a result of the rapid and uncoordinated beating of the atria of the heart, which can lead to blood pooling in the LAA AF is a recognized independent risk factor for stroke, and about 35 % of patients with this irregular heart rhythm will have a stroke in their lifetime.As with all medications, be Decision stopping or modify not discussed with a doctor discussed with a doctor. Forward Glaxo Smith Kline one of the leading global research-based pharmaceutical and health care companies improve the quality of life of enabling people, more obligated to do, feel better and live longer.

Related Posts

Other Posts From Category "ozone therapy":